Lung cancer vaccine may come soon, UK human trial begins

Lung Cancer Vaccine: The world’s first vaccine to cure lung cancer may come very soon. Human trials of this lung cancer vaccine have started. The name of this vaccine is BNT116, which is being made by BioNTech. This vaccine is for the treatment of non-small cell lung cancer (NSCLC). The first phase trial of BNT116 is going on at 34 sites in UK, USA, Germany, Hungary, Poland, Spain and Turkey.

Let us tell you that lung cancer is the biggest cause of cancer deaths worldwide. Due to this, about 1.8 million deaths occur every year. Let us know everything about this vaccine…

Human trial of lung cancer vaccine

The first patient in Britain was vaccinated on Tuesday. Around 130 patients in the UK will be given BNT116 along with immunotherapy in different phases of lung cancer. Using the same mRNA technology as the Covid-19 vaccine, BNT116 aims to enable the immune system to target NSCLC tumor markers, attacking cancer cells while leaving healthy cells unharmed.

How the lung cancer vaccine was trialled

Janusz Racz, a 67-year-old AI scientist from London, was the first UK patient to receive the vaccine. He decided to join the trial after being diagnosed with lung cancer in May and starting chemotherapy and radiotherapy. Racz was given six injections over 30 minutes at the National Institute for Health Research UCLH Clinical Research Facility, each containing different RNA strands. He will receive the vaccine by giving it weekly for six weeks. The treatment will then be given every three weeks for over a year.

what do the doctors say

Professor Seo Ming, of University College London Hospitals NHS Foundation Trust (UCLH), told The Guardian: ‘We are entering a new era with mRNA-based immunotherapy for lung cancer.’ Professor Seo Ming Lee, a consultant medical oncologist at University College London Hospitals NHS Foundation Trust, who is leading the trial in the UK, said the aim is to prevent lung cancer from coming back, which often happens even after surgery and radiation. He said: ‘I have studied lung cancer for 40 years.

In the 1990s, chemotherapy was questionable. Now we know that 20-30% of stage 4 patients survive immunotherapy. The hope is that this mRNA vaccine will further increase survival rates.’ This trial is part of the UK’s effort to accelerate the process of getting patients into innovative cancer vaccine testing through the new NHS matchmaking plan, which is vital to patients’ lives.’

Disclaimer: Some of the information given in the news is based on media reports. Before implementing any suggestion, please consult the concerned expert.

Also read: Monkeypox: If monkeypox enters India, what will be its impact, know how its entry can be stopped